SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing significant volatility and renewed retail interest, driven by speculation surrounding upcoming supply-reducing burn mechanisms and potential legal developments. Community sentiment remains polarized, with many long-term holders expressing optimism about a potential price resurgence while skeptics continue to warn of historical risks and the speculative nature of the current momentum.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is gaining attention following the announced preliminary design for the Phase 3 trial of CAD-1005, which aims to treat heparin-induced thrombocytopenia. While some community members are optimistic about the clinical pathway and upcoming milestones, others are expressing skepticism regarding promotional activity and potential future financing requirements.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

The community is actively discussing the reliable monthly dividend payouts and the strategy of building a layered income engine using JEPQ alongside other high-yield equity ETFs. Investors are expressing confidence in its consistent performance as a core income holding while sharing tips on dividend reinvestment strategies and portfolio balancing for long-term passive cash flow.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is attracting significant investor attention as it navigates a broader software sector reset, with the community actively debating whether its AI-integrated observability platform can maintain premium growth or if it remains vulnerable to valuation compression. Traders are closely watching upcoming earnings as a key catalyst to determine if the stock will find a sustainable bottom or continue to face pressure from ongoing enterprise spending scrutiny.

Roundhill ETF Trust - Roundhill Memory ETF

The Roundhill Memory ETF is seeing a surge in retail interest as investors seek direct exposure to a perceived multi-year 'memory super-cycle' driven by insatiable AI demand. Fintwit community discussions highlight memory as the primary bottleneck for data centers, with many aggressively accumulating the ETF to capitalize on the concentrated growth of HBM leaders like SK Hynix, Samsung, and Micron.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending as investors closely track upcoming Senate markups for the Clarity Act, with community sentiment divided between optimistic anticipation of regulatory breakthroughs and frustration over prolonged price stagnation. Participants are intensely debating whether the current accumulation phase and institutional interest will trigger a significant breakout or if the asset will continue to underperform broader market moves.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following reports that the company is quietly building a stake in eBay for a potential takeover, fueling community debate about the viability of such a massive acquisition. While some investors see this as a bold move to leverage GameStop's cash reserves for a transformation into a retail giant, others are skeptical of the math and potential dilution, leading to intense speculation about short positions and the company's long-term strategy.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending as investors weigh Jamie Dimon's cautious macro outlookhighlighting risks from energy volatility and geopolitical tensionsagainst the bank's resilient trading performance and strong balance sheet. The community is actively debating the bank's role in private credit exposure and its potential systemic influence as markets navigate uncertain rate trajectories.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as investors weigh potential buyout and leadership change speculation against concerns over sluggish sales, debt levels, and the absence of a permanent CEO. While some market participants express frustration over the stock's recent downward trajectory and lack of catalyst, others view the current price as a value opportunity supported by a solid dividend, international expansion efforts, and significant short interest that could drive a squeeze.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as investors monitor a critical patent infringement case currently before the Supreme Court, with the community actively debating whether the potential for a favorable ruling or an eventual acquisition creates an asymmetric risk-reward opportunity. Market participants are closely analyzing recent financial stabilization and strategic restructuring efforts as indicators of the company's long-term valuation potential while navigating persistent generic competition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pictet Asset Management Holding SA Lowers Position in NewAmsterdam Pharma Company N.V. $NAMS

Pictet Asset Management Holding SA trimmed its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 42.3% in the 4th quarter, according to the company in its most...

Jennison Associates LLC Trims Stock Position in NewAmsterdam Pharma Company N.V. $NAMS

Jennison Associates LLC trimmed its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 16.9% during the 4th quarter, according to the company in its most recent...

NewAmsterdam Pharma (NAMS) Expected to Announce Earnings on Thursday

NewAmsterdam Pharma (NASDAQ:NAMS) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...

143,549 Shares in NewAmsterdam Pharma Company N.V. $NAMS Bought by Moody Aldrich Partners LLC

Moody Aldrich Partners LLC bought a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 143,549 shares of the company's stock, valued at approximately...

NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 8% - What's Next?

NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 8% - Should You Sell...

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Rating of "Moderate Buy" from Analysts

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twelve analysts that are currently covering the company...

Aberdeen Group plc Has $25.59 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS

Aberdeen Group plc grew its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 10.2% during the fourth quarter, according to its most recent disclosure with the Securities...

JPMorgan Chase & Co. Trims Stock Position in NewAmsterdam Pharma Company N.V. $NAMS

JPMorgan Chase & Co. cut its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 10.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,302,498 shares of the company's stock after sell...

NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Truist Financial

Truist Financial assumed coverage on NewAmsterdam Pharma in a research report on Wednesday. They set a "buy" rating and a $57.00 price target on the stock...

NewAmsterdam Pharma Company N.V. $NAMS is Decheng Capital LLC's 5th Largest Position

Decheng Capital LLC trimmed its position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 14.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with...

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.

NAMS
NewAmsterdam Pharma Company NV

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NAMS News

NAMSNewAmsterdam Pharma Company NV